Famotidine neither affects action potential parameters nor inhibits human ether-a-go-go-related gene (hERG) K+ current

Journal of Toxicological Sciences

Volumn 34, Issue 5, 2009, Pages 563-567

  Nakamura, Yuji ^a   Takahara, Akira ^a   Sugiyama, Atsushi ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Action potential duration; Famotidine; hERG; QT interval; Torsades de pointes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; DIMETHYL SULFOXIDE; FAMOTIDINE; POTASSIUM CHANNEL HERG;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; FEMALE; GUINEA PIG; HEART PAPILLARY MUSCLE; HEART REPOLARIZATION; MALE; NONHUMAN; POTASSIUM CURRENT;

CAVIA; CRICETULUS GRISEUS;

EID: 70349907934     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.34.563     Document Type: Article

References (10)

1. Kr) channel. J. Cardiovasc. Electrophysiol., 15, 1302-1309.
2. Endo, T., Katoh, T., Kiuchi, K., Katsuta, Y., Shimizu, S. and Takano, T. (2000): Famotidine and acquired long QT syndrome. Am. J. Med., 108, 438-439.
3. Howden, C.W. and Tytgat, G.N. (1996): The tolerability and safety profile of famotidine. Clin. Ther., 18, 36-54.
4. Katayama, Y., Tsuzaki, T., Abe, K., Tomizawa, S., Izumi, T. and Tsurubuchi, Y. (2005): The inter-cell-line reproducibility of hERG assay using the whole-cell patch-clamping. J. Pharmacol. Sci., 97 (Suppl), 236P.
5. Langtry, H.D., Grant, S.M. and Goa, K.L. (1989): Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs, 38, 551-591.
6. Lee, K.W., Kayser, S.R., Hongo, R.H., Tseng, Z.H. and Scheinman, M.M. (2004): Famotidine and long QT syndrome. Am. J. Cardiol., 93, 1325-1327.
7. Kr and cloned HERG current. Naunyn Schmiedebergs Arch. Pharmacol., 370, 492-499.
8. Shimizu, S., Takahashi, Y., Nakamura, M. and Fujino, A. (2005): Difference of inhibitory effects on HERG potassium channel transfected in HEK 293 and CHO-K1 cells. J. Pharmacol. Sci., 97 (Suppl), 236P.
9. Sugiyama, A., Satoh, Y., Takahara, A., Nakamura, Y., ShimizuSasamata, M., Sato, S., Miyata, K. and Hashimoto, K. (2003): Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems. Eur. J. Pharmacol., 466, 137-146.
10. Zhang, S., Zhou, Z., Gong, Q., Makielski, J.C. and January, C.T. (1999): Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res., 84, 989-998.